Live signal feed

The chain others read separately, joined in time.

NIH grant → clinical trial → public-company event. We snapshot all three daily and surface the upstream move before the downstream one is news. Last snapshot 2026-06-21 · 42 signals · 80 grants, 152 trials, 10433 tickers indexed.

⚠ Research/informational signals from public data (NIH · ClinicalTrials.gov · SEC EDGAR). Not investment advice. Full scope →

Trial → FilingONC55% conf

BeOne Medicines Ltd. (ONC) — PHASE2 primary completion in ~133 days

Upstream (observed)
Clinical trial status (PHASE2) — A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

↓ Phase-transition base rate 28% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on Phase 3 initiation (18-36 mo, base rate 28%)

trial ↗filings ↗

Trial → FilingBIOA55% conf

BioAge Labs, Inc. (BIOA) — PHASE2 primary completion in ~162 days

Upstream (observed)
Clinical trial status (PHASE2) — A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors

↓ Phase-transition base rate 28% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on Phase 3 initiation (18-36 mo, base rate 28%)

trial ↗filings ↗

Trial → FilingREGN55% conf

REGENERON PHARMACEUTICALS, INC. (REGN) — PHASE2 primary completion in ~145 days

Upstream (observed)
Clinical trial status (PHASE2) — Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US

↓ Phase-transition base rate 28% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on Phase 3 initiation (18-36 mo, base rate 28%)

trial ↗filings ↗

Trial → FilingLLY55% conf

ELI LILLY & Co (LLY) — PHASE1 primary completion in ~41 days

Upstream (observed)
Clinical trial status (PHASE1) — A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes

↓ Phase-transition base rate 52% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on Phase 2 readout / advance (12-24 mo, base rate 52%)

trial ↗filings ↗

Trial → FilingNVO55% conf

NOVO NORDISK A S (NVO) — trial primary completion in ~10 days

Upstream (observed)
Clinical trial status (n/a) — A Real-world Study to Investigate Cardiovascular Risk Profile Among Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) Participants

↓ days–weeks to disclosure

Predicted downstream
SEC 8-K / press release (material trial update) (days–weeks)

trial ↗filings ↗

Trial → FilingABBV35% conf

AbbVie Inc. (ABBV) — PHASE2 protocol updated 3 days ago

Upstream (observed)
Clinical trial status (PHASE2) — A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer

↓ Phase-transition base rate 28% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on Phase 3 initiation (18-36 mo, base rate 28%)

trial ↗filings ↗

Trial → FilingAMGN35% conf

AMGEN INC (AMGN) — PHASE3 protocol updated 3 days ago

Upstream (observed)
Clinical trial status (PHASE3) — A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

↓ Phase-transition base rate 57% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on NDA/BLA filing (FDA submission) (12-24 mo, base rate 57%)

trial ↗filings ↗

Trial → FilingIMNM35% conf

Immunome Inc. (IMNM) — EARLY_PHASE1 protocol updated 3 days ago

Upstream (observed)
Clinical trial status (EARLY_PHASE1) — A Phase 1 Study of 177Lu-IM-3050 in Participants With Advanced Cancer

↓ days–weeks to disclosure

Predicted downstream
SEC 8-K / press release (material trial update) (days–weeks)

trial ↗filings ↗

Trial → FilingLLY35% conf

ELI LILLY & Co (LLY) — PHASE3 protocol updated 3 days ago

Upstream (observed)
Clinical trial status (PHASE3) — A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities

↓ Phase-transition base rate 57% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on NDA/BLA filing (FDA submission) (12-24 mo, base rate 57%)

trial ↗filings ↗

Trial → FilingLLY35% conf

ELI LILLY & Co (LLY) — PHASE3 protocol updated 3 days ago

Upstream (observed)
Clinical trial status (PHASE3) — A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)

↓ Phase-transition base rate 57% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on NDA/BLA filing (FDA submission) (12-24 mo, base rate 57%)

trial ↗filings ↗

Trial → FilingAMGN35% conf

AMGEN INC (AMGN) — PHASE3 protocol updated 3 days ago

Upstream (observed)
Clinical trial status (PHASE3) — Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

↓ Phase-transition base rate 57% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on NDA/BLA filing (FDA submission) (12-24 mo, base rate 57%)

trial ↗filings ↗

Trial → FilingKLRA35% conf

Kailera Therapeutics, Inc. (KLRA) — PHASE3 protocol updated 3 days ago

Upstream (observed)
Clinical trial status (PHASE3) — Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes

↓ Phase-transition base rate 57% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on NDA/BLA filing (FDA submission) (12-24 mo, base rate 57%)

trial ↗filings ↗

Trial → FilingAMGN35% conf

AMGEN INC (AMGN) — PHASE2 protocol updated 3 days ago

Upstream (observed)
Clinical trial status (PHASE2) — A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight

↓ Phase-transition base rate 28% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on Phase 3 initiation (18-36 mo, base rate 28%)

trial ↗filings ↗

Trial → FilingKLRA35% conf

Kailera Therapeutics, Inc. (KLRA) — PHASE3 protocol updated 3 days ago

Upstream (observed)
Clinical trial status (PHASE3) — Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes

↓ Phase-transition base rate 57% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on NDA/BLA filing (FDA submission) (12-24 mo, base rate 57%)

trial ↗filings ↗

Trial → FilingKLRA35% conf

Kailera Therapeutics, Inc. (KLRA) — PHASE3 protocol updated 3 days ago

Upstream (observed)
Clinical trial status (PHASE3) — Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes

↓ Phase-transition base rate 57% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on NDA/BLA filing (FDA submission) (12-24 mo, base rate 57%)

trial ↗filings ↗

Trial → FilingLLY35% conf

ELI LILLY & Co (LLY) — PHASE3 protocol updated 3 days ago

Upstream (observed)
Clinical trial status (PHASE3) — A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

↓ Phase-transition base rate 57% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on NDA/BLA filing (FDA submission) (12-24 mo, base rate 57%)

trial ↗filings ↗

Trial → FilingLLY35% conf

ELI LILLY & Co (LLY) — PHASE3 protocol updated 4 days ago

Upstream (observed)
Clinical trial status (PHASE3) — The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

↓ Phase-transition base rate 57% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on NDA/BLA filing (FDA submission) (12-24 mo, base rate 57%)

trial ↗filings ↗

Trial → FilingKLRA35% conf

Kailera Therapeutics, Inc. (KLRA) — PHASE2 protocol updated 5 days ago

Upstream (observed)
Clinical trial status (PHASE2) — Efficacy and Safety of Oral KAI-7535 in Adult Participants Living With Obesity or Overweight With at Least 1 Weight-Related Comorbidity

↓ Phase-transition base rate 28% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on Phase 3 initiation (18-36 mo, base rate 28%)

trial ↗filings ↗

Trial → FilingNVO35% conf

NOVO NORDISK A S (NVO) — PHASE3 protocol updated 5 days ago

Upstream (observed)
Clinical trial status (PHASE3) — A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight

↓ Phase-transition base rate 57% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on NDA/BLA filing (FDA submission) (12-24 mo, base rate 57%)

trial ↗filings ↗

Trial → FilingLLY35% conf

ELI LILLY & Co (LLY) — PHASE3 protocol updated 3 days ago

Upstream (observed)
Clinical trial status (PHASE3) — A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)

↓ Phase-transition base rate 57% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on NDA/BLA filing (FDA submission) (12-24 mo, base rate 57%)

trial ↗filings ↗

Trial → FilingLLY35% conf

ELI LILLY & Co (LLY) — PHASE2 protocol updated 4 days ago

Upstream (observed)
Clinical trial status (PHASE2) — A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)

↓ Phase-transition base rate 28% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on Phase 3 initiation (18-36 mo, base rate 28%)

trial ↗filings ↗

Trial → FilingLLY35% conf

ELI LILLY & Co (LLY) — PHASE1 protocol updated 5 days ago

Upstream (observed)
Clinical trial status (PHASE1) — A Study of LY3439539 in Participants With Alzheimer's Disease

↓ Phase-transition base rate 52% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on Phase 2 readout / advance (12-24 mo, base rate 52%)

trial ↗filings ↗

Trial → FilingACAD35% conf

ACADIA PHARMACEUTICALS INC (ACAD) — PHASE3 protocol updated 5 days ago

Upstream (observed)
Clinical trial status (PHASE3) — ACP-204 in Adults With Alzheimer's Disease Psychosis

↓ Phase-transition base rate 57% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on NDA/BLA filing (FDA submission) (12-24 mo, base rate 57%)

trial ↗filings ↗

Trial → FilingBMY35% conf

BRISTOL MYERS SQUIBB CO (BMY) — PHASE3 protocol updated 5 days ago

Upstream (observed)
Clinical trial status (PHASE3) — A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)

↓ Phase-transition base rate 57% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on NDA/BLA filing (FDA submission) (12-24 mo, base rate 57%)

trial ↗filings ↗

Trial → FilingABBV35% conf

AbbVie Inc. (ABBV) — PHASE2 protocol updated 6 days ago

Upstream (observed)
Clinical trial status (PHASE2) — A Study to Assess the Safety and Effects of ABBV-1758 Following Subcutaneous or Intravenous Injections in Participants With Alzheimer's Disease

↓ Phase-transition base rate 28% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on Phase 3 initiation (18-36 mo, base rate 28%)

trial ↗filings ↗

Trial → FilingALNY35% conf

ALNYLAM PHARMACEUTICALS, INC. (ALNY) — PHASE1 protocol updated 9 days ago

Upstream (observed)
Clinical trial status (PHASE1) — A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD

↓ Phase-transition base rate 52% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on Phase 2 readout / advance (12-24 mo, base rate 52%)

trial ↗filings ↗

Trial → FilingALNY35% conf

ALNYLAM PHARMACEUTICALS, INC. (ALNY) — PHASE1 protocol updated 9 days ago

Upstream (observed)
Clinical trial status (PHASE1) — A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease

↓ Phase-transition base rate 52% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on Phase 2 readout / advance (12-24 mo, base rate 52%)

trial ↗filings ↗

Trial → FilingBMY35% conf

BRISTOL MYERS SQUIBB CO (BMY) — PHASE3 protocol updated 11 days ago

Upstream (observed)
Clinical trial status (PHASE3) — A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)

↓ Phase-transition base rate 57% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on NDA/BLA filing (FDA submission) (12-24 mo, base rate 57%)

trial ↗filings ↗

Trial → FilingLLY35% conf

ELI LILLY & Co (LLY) — PHASE3 protocol updated 3 days ago

Upstream (observed)
Clinical trial status (PHASE3) — A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)

↓ Phase-transition base rate 57% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on NDA/BLA filing (FDA submission) (12-24 mo, base rate 57%)

trial ↗filings ↗

Area heat50% conf

"obesity" heating up — 0 grants ($0), 34 active trials (19 started <12 mo)

Upstream (observed)
NIH grant velocity — 0 grants, $0 in window

↓ 12–24 mo to BD/commercial activity (directional)

Predicted downstream
Elevated M&A / licensing / IPO activity in this mechanism over 12–24 mo (12–24 mo)

Area heat50% conf

"Alzheimer" heating up — 8 grants ($219,644,270), 34 active trials (13 started <12 mo)

Upstream (observed)
NIH grant velocity — 8 grants, $219,644,270 in window

↓ 12–24 mo to BD/commercial activity (directional)

Predicted downstream
Elevated M&A / licensing / IPO activity in this mechanism over 12–24 mo (12–24 mo)

Grant → Trial42% conf

NIH-funded research entered the clinic: "BOLSTER: Learning New Skills to Thrive"

Upstream (observed)
NIH RePORTER grant — NATIONAL CANCER INSTITUTE — Biomedical Information Technology, Software Development, and Informatics Support (FY2025, $30,861,067) · joined via same funded organization

↓ Grant→trial typically 1–3 yr (translational); now realized — next watch is phase readout.

Predicted downstream
phase advance / readout (12–24 mo)

trial ↗grant ↗

Grant → Trial42% conf

NIH-funded research entered the clinic: "The Effects of Strength Training on Muscle Mass and Mental Health in Adults Taking Obesit…"

Upstream (observed)
NIH RePORTER grant — UNIVERSITY OF PITTSBURGH AT PITTSBURGH — Alzheimer Biomarker Consortium - Down Syndrome (ABC-DS) (FY2025, $17,980,649) · joined via same funded organization

↓ Grant→trial typically 1–3 yr (translational); now realized — next watch is phase readout.

Predicted downstream
phase advance / readout (12–24 mo)

trial ↗grant ↗

Grant → Trial42% conf

NIH-funded research entered the clinic: "PRImary Care Strategies for Weight Management (PRISM) Study"

Upstream (observed)
NIH RePORTER grant — VANDERBILT UNIVERSITY MEDICAL CENTER — All of Us Research Program Data and Research Center (FY2025, $40,678,454) · joined via same funded organization

↓ Grant→trial typically 1–3 yr (translational); now realized — next watch is phase readout.

Predicted downstream
phase advance / readout (12–24 mo)

trial ↗grant ↗

Grant → Trial42% conf

NIH-funded research entered the clinic: "Body Composition Outcomes in MS Patients"

Upstream (observed)
NIH RePORTER grant — LEIDOS BIOMEDICAL RESEARCH, INC. — NCI-Frederick Operational Support (FY2025, $82,503,495) · joined via same funded organization

↓ Grant→trial typically 1–3 yr (translational); now realized — next watch is phase readout.

Predicted downstream
phase advance / readout (12–24 mo)

trial ↗grant ↗

Grant → Trial42% conf

NIH-funded research entered the clinic: "Cerebrospinal Fluid Mitochondrial Biomarkers in Ischemic Stroke and Alzheimer Disease"

↓ Grant→trial typically 1–3 yr (translational); now realized — next watch is phase readout.

Predicted downstream
phase advance / readout (12–24 mo)

trial ↗grant ↗

Grant → Trial42% conf

NIH-funded research entered the clinic: "Olfactory Biopsies"

Upstream (observed)
NIH RePORTER grant — DUKE UNIVERSITY — Induction of protective antibodies for HIV vaccine development (FY2025, $20,752,000) · joined via same funded organization

↓ Grant→trial typically 1–3 yr (translational); now realized — next watch is phase readout.

Predicted downstream
phase advance / readout (12–24 mo)

trial ↗grant ↗

Grant → Trial42% conf

NIH-funded research entered the clinic: "Polyphenols and Cognitive Decline"

Upstream (observed)
NIH RePORTER grant — UNIVERSITY OF CALIFORNIA LOS ANGELES — Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (FY2025, $36,436,959) · joined via same funded organization

↓ Grant→trial typically 1–3 yr (translational); now realized — next watch is phase readout.

Predicted downstream
phase advance / readout (12–24 mo)

trial ↗grant ↗

Grant → Trial42% conf

NIH-funded research entered the clinic: "Anti-inflammatory Dietary Intervention in Patients With Type 2 Diabetes: A Randomized Con…"

↓ Grant→trial typically 1–3 yr (translational); now realized — next watch is phase readout.

Predicted downstream
phase advance / readout (12–24 mo)

trial ↗grant ↗

Grant → Trial42% conf

NIH-funded research entered the clinic: "Rezpegaldesleukin (NKTR-358) in New Onset Type 1 Diabetes Mellitus"

Upstream (observed)
NIH RePORTER grant — NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES — NIAID CCMF allocation (FY2025, $118,430,841) · joined via same funded organization

↓ Grant→trial typically 1–3 yr (translational); now realized — next watch is phase readout.

Predicted downstream
Phase 3 initiation (18-36 mo, base rate 28%)

trial ↗grant ↗

Area heat26% conf

"GLP-1" heating up — 0 grants ($0), 2 active trials (2 started <12 mo)

Upstream (observed)
NIH grant velocity — 0 grants, $0 in window

↓ 12–24 mo to BD/commercial activity (directional)

Predicted downstream
Elevated M&A / licensing / IPO activity in this mechanism over 12–24 mo (12–24 mo)

Area heat23% conf

"immunotherapy" heating up — 0 grants ($0), 3 active trials (1 started <12 mo)

Upstream (observed)
NIH grant velocity — 0 grants, $0 in window

↓ 12–24 mo to BD/commercial activity (directional)

Predicted downstream
Elevated M&A / licensing / IPO activity in this mechanism over 12–24 mo (12–24 mo)